
ASLAN Pharmaceuticals Limited ASLN
Geschäftsbericht 2020
hinzugefügt 19.08.2023
ASLAN Pharmaceuticals Limited Betriebsaufwand 2011-2026 | ASLN
Betriebsaufwand Jährlich ASLAN Pharmaceuticals Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 33.8 M | 16.5 M | 25.1 M | 42.3 M | 39.1 M | 20 M | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 42.3 M | 16.5 M | 29.5 M |
Betriebsaufwand anderer Aktien in der Pharmaeinzelhändler
| Name | Betriebsaufwand | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
65.1 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
338 M | $ 219.68 | 1.92 % | $ 5 B | ||
|
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | ||
|
Seres Therapeutics
MCRB
|
234 M | $ 8.28 | - | $ 1.06 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
216 M | $ 19.45 | 1.14 % | $ 909 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | ||
|
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
10.1 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | ||
|
Mesoblast Limited
MESO
|
86.7 M | $ 15.44 | 7.82 % | $ 10 B | ||
|
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B | ||
|
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | ||
|
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - | ||
|
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
8.73 M | $ 0.67 | -5.25 % | $ 7.67 M | ||
|
Mirum Pharmaceuticals
MIRM
|
543 M | $ 90.39 | 2.86 % | $ 4.54 B | ||
|
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.34 | 1.52 % | $ 342 M | ||
|
MediciNova
MNOV
|
13.7 M | $ 1.45 | - | $ 71.1 M | ||
|
CytomX Therapeutics
CTMX
|
98.6 M | $ 4.37 | 2.95 % | $ 603 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
12 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | ||
|
Aytu BioScience
AYTU
|
53.7 M | $ 2.69 | 1.37 % | $ 16.9 M | ||
|
Dynavax Technologies Corporation
DVAX
|
137 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | ||
|
Merck & Co.
MRK
|
20.5 B | $ 117.56 | 1.02 % | $ 294 B | ||
|
Marker Therapeutics
MRKR
|
16.4 M | $ 1.37 | 8.73 % | $ 21 M | ||
|
Moderna
MRNA
|
606 M | $ 53.09 | 3.41 % | $ 20.7 B | ||
|
Bellerophon Therapeutics
BLPH
|
22.4 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
52.2 M | $ 4.47 | 3.71 % | $ 856 M | ||
|
Homology Medicines
FIXX
|
36.8 M | - | 0.77 % | $ 53.4 M |